Jefferies Financial Group Inc. Invests $473,000 in Roivant Sciences Ltd. (NASDAQ:ROIV)
Jefferies Financial Group Inc. bought a new position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 40,000 shares of the company's stock, valued at approximately $473,000.
A number of other institutional investors also recently bought and sold shares of the stock. Barclays PLC lifted its stake in Roivant Sciences by 19.7% during the 3rd quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after acquiring an additional 75,609 shares during the period. Wedmont Private Capital purchased a new position in Roivant Sciences during the fourth quarter valued at $134,000. Miracle Mile Advisors LLC purchased a new position in Roivant Sciences during the fourth quarter valued at $148,000. Penn Davis Mcfarland Inc. lifted its holdings in Roivant Sciences by 1.0% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 1,649,026 shares of the company's stock valued at $19,508,000 after purchasing an additional 16,832 shares in the last quarter. Finally, Impact Partnership Wealth LLC purchased a new position in Roivant Sciences during the fourth quarter valued at $222,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.
ROIV opened at $10.79 on Friday. The firm has a market capitalization of $7.70 billion, a PE ratio of -71.93 and a beta of 1.23. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $13.06. The firm's 50-day moving average price is $10.51 and its 200 day moving average price is $11.08.
Several equities analysts have recently weighed in on ROIV shares. HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Monday, April 21st. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th.
Check Out Our Latest Report on Roivant Sciences
In other Roivant Sciences news, COO Eric Venker sold 315,522 shares of the business's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $11.06, for a total value of $3,489,673.32. Following the transaction, the chief operating officer now directly owns 959,457 shares in the company, valued at $10,611,594.42. The trade was a 24.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the business's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the completion of the transaction, the insider now owns 39,799,611 shares in the company, valued at $456,501,538.17. The trade was a 0.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,223,959 shares of company stock worth $13,420,035. 7.90% of the stock is owned by insiders.
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
